Nebraska Newborn Screening

September 26, 2024

LSD Coalition Created and Brian Jones is Treasurer

Our Newborn Screening Coordinator, Rachelen Varghese, presented to the Newborn Screening and Genetics committee in Nebraska on July 25th, 2023. The presentation covered in-depth facts about Fabry Disease, positive consequences of receiving timely therapy and the negative impact of delayed screening. The committee was very gracious in receiving the information and posed several introspective questions at the end. Our need is to find a physician, local to Nebraska, who is a voting member of the committee and can nominate the condition for consideration for inclusion in the state’s newborn screening panel. In the meantime, Rachelen will be reviewing economist papers to address concerns about cost versus insurance coverage of treatment in the state of Nebraska. Additional research will hopefully cover studies of patients from the time of ERT (Enzyme Replacement Therapy) initiation to end of life and ethics about family testing. We would be grateful to connect with local patients to understand the cost of Galafold vs ERT treatment and necessary support from facilities and healthcare providers. If you are a Nebraska resident and affected by Fabry Disease, please reach out to us via testingfortots@gmail.com.

Logo for Candid: Platinum Transparency 2025 in a blue-bordered white square.
November 20, 2025
FSIG Achieves Candid’s Platinum Seal of Transparency
September 26, 2024
LSD Coalition Created and Brian Jones is Treasurer 
September 26, 2024
This September marks the 50th anniversary of newborn screening. Here at the Testing for Tots program, we believe that early detection, diagnosis and intervention can prevent death or disability and enable children to reach their full potential. Rare, and mostly treatable conditions , are screened for within the first 1-2 days after birth. All it takes is a few drops of blood from a heel stick that is then reviewed in the associated laboratory for serious conditions. (The comprehensive newborn screening panel consists of 3 parts – blood test, hearing and pulse oximetry screens). Although these conditions are rare, about 5,000 babies are diagnosed each year with a rare condition. Newborn screening is a critical tool in the belt of the rare disease community. The number of conditions screened vary from state to state. Our team has been working on adding Fabry Disease in multiple states across the nation (Georgia, Massachusetts, South Carolina, Utah, Colorado, Nebraska, and Wisconsin). If you are interested in supporting our initiatives or partnering with us for your home state, email us at testingfortots@gmail.com .